Ilkka Kantola

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 589 citations · Full text

Urology, Renal Disease, Renal Events +7

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document

Marieke Biegstraaten, Reynir Arngrı́msson, Frédéric Barbey et al. · Orphanet Journal of Rare Diseases · 2015 · 335 citations · Full text

Shoulder capsulitis in type I and II diabetic patients: association with diabetic complications and related diseases.

Perttu Arkkila, Ilkka Kantola, Jorma Viikari et al. · Annals of the Rheumatic Diseases · 1996 · 209 citations · Full text

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

Markus P. Schlaich, M Bellet, Michael A. Weber et al. · The Lancet · 2022 · 206 citations · Full text

Molecular Pharmacology, Hypertension, Resistant Hypertension +9

Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

Raphael Schiffmann, Derralynn Hughes, Gabor E. Linthorst et al. · Kidney International · 2016 · 175 citations